UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $20.49 Million Stock Holdings in Biohaven Ltd. (NYSE:BHVN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Biohaven Ltd. (NYSE:BHVN - Free Report) by 7.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 548,575 shares of the company's stock after buying an additional 39,953 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.54% of Biohaven worth $20,489,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Spire Wealth Management acquired a new position in Biohaven in the fourth quarter worth approximately $56,000. Amalgamated Bank increased its holdings in Biohaven by 21.9% in the fourth quarter. Amalgamated Bank now owns 2,929 shares of the company's stock worth $109,000 after buying an additional 527 shares during the last quarter. US Bancorp DE increased its holdings in Biohaven by 36.7% in the fourth quarter. US Bancorp DE now owns 2,971 shares of the company's stock worth $111,000 after buying an additional 798 shares during the last quarter. Quarry LP acquired a new position in Biohaven in the fourth quarter worth approximately $112,000. Finally, Lazard Asset Management LLC increased its holdings in Biohaven by 47.4% in the fourth quarter. Lazard Asset Management LLC now owns 3,207 shares of the company's stock worth $119,000 after buying an additional 1,031 shares during the last quarter. Institutional investors and hedge funds own 88.78% of the company's stock.

Insider Activity

In other Biohaven news, Director John W. Childs acquired 32,700 shares of the company's stock in a transaction dated Tuesday, March 4th. The stock was bought at an average price of $30.47 per share, for a total transaction of $996,369.00. Following the purchase, the director now owns 2,320,571 shares in the company, valued at $70,707,798.37. This represents a 1.43% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 16.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Cantor Fitzgerald upgraded Biohaven to a "strong-buy" rating in a report on Tuesday, May 13th. Robert W. Baird decreased their target price on Biohaven from $60.00 to $57.00 and set an "outperform" rating for the company in a research report on Monday, April 28th. William Blair raised Biohaven to a "strong-buy" rating in a research report on Thursday, April 24th. Morgan Stanley decreased their target price on Biohaven from $69.00 to $63.00 and set an "overweight" rating for the company in a research report on Friday, March 7th. Finally, Deutsche Bank Aktiengesellschaft set a $60.00 target price on Biohaven and gave the stock a "buy" rating in a research report on Thursday, March 20th. One research analyst has rated the stock with a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Biohaven presently has an average rating of "Buy" and a consensus price target of $59.46.

Biohaven Stock Performance

Shares of BHVN traded up $0.09 during mid-day trading on Friday, hitting $14.83. The company's stock had a trading volume of 2,458,064 shares, compared to its average volume of 1,222,698. Biohaven Ltd. has a one year low of $14.33 and a one year high of $55.70. The firm has a market capitalization of $1.51 billion, a PE ratio of -1.59 and a beta of 1.18. The stock's 50-day moving average is $19.56 and its two-hundred day moving average is $31.58.

Biohaven (NYSE:BHVN - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($2.17) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.50). Analysts expect that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.